Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

Summary

The Haemato Oncology Foundation for Adults in the Netherlands (HOVON) has designed this study. Researchers (all doctors) are conducting the study at various hospitals in the Netherlands, Denmark and Sweden. The study medicines pirtobrutinib and epcoritamab that are used in this study are made available by pharmaceutical companies Eli Lilly and AbbVie. This study is also funded by AbbVie and Eli Lilly. HOVON needs 70 participants for this study. The purpose of this study is to find out how safe and effective the combination of pirtobrutinib tablets and subcutaneous epcoritamab is for patients with CLL whose disease has come back after previous treatment or whose disease did not respond well to the previous treatment. The goal is to suppress the CLL to such an extent that the disease does not come back for a long time.

Timeline

Start

2026-09-15

Primary completion

2030-10-15

Completion

2032-10-15

Drugs

Indications